Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...